FitLife Brands Sees FY24 Revenue $64M-$65M, Up 21%-23% YoY

Benzinga
03-13

FitLife Brands, Inc. ("FitLife," or the "Company") (NASDAQ:FTLF), a provider of innovative and proprietary nutritional supplements and wellness products, today announced that it will participate in the 37th Annual Roth Conference on Monday and Tuesday, March 17-18, 2025.  Investors who are interested in meeting with FitLife management should submit their requests through their Roth representative.

In conjunction with its participation in the conference, the Company has prepared an updated investor presentation which will be filed with the Securities and Exchange Commission on Form 8-K in advance of the conference. 

The Company plans to report its financial performance for the fourth quarter and full year of 2024 with the Securities and Exchange Commission on Form 10-K on March 27, 2025.  However, in order to facilitate upcoming investor discussions, the Company is providing the following financial and operational update regarding the Company's recent performance:

  • Net revenue for the full year 2024 is anticipated to be between $64-65 million, an increase of 21-23% compared to 2023.
  • Adjusted EBITDA for the full year 2024 is anticipated to be between $14.0-14.2 million, an increase of 38-40% compared to 2023.
  • Net income for the full year 2024 is anticipated to be between $8.9-9.1 million, an increase of 68-72% compared to 2023.
  • As of December 31st, 2024, the Company had $13.1 million outstanding on its term loan and no balance outstanding on its revolver.
  • As of December 31st, 2024, the Company had $4.5 million of cash.
    • Shares outstanding as of March 12, 2025 were 9,218,528.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10